Gregory A. Bonfiglio

Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC. Mr. Bonfiglio was an early investor in the field of stems cell & regenerative medicine, and he continues to actively invest in the field. Proteus is raising a new early stage, venture fund focused exclusively on regenerative medicines. Mr. Bonfiglio is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine, a RM Translation Center in Toronto, Canada. He is a Member of the ISSCR and is on their Advisory Board, as well as their Finance Committee. He also is a Member of the ISCT. Mr. Bonfiglio has served on the Boards of several RM companies, including VistaGen Therapeutics (in vitro tools from hESCs); California Stem Cell (hESC tools & therapeutics); and StemCyte, Inc. (cord blood storage & therapeutics). Mr. Bonfiglio is a frequent speaker at Regenerative Medicine Conferences. In 2013, Mr. Bonfiglio was listed among the Top 50 Stem Cell Influencers in the world (Ranked 14th).

From 2000 – 2005, Mr. Bonfiglio was a General Partner with Anthem Venture Partners – an early stage venture fund in California. Mr. Bonfiglio led Anthem’s investment in Advanced Cell Technology in 2000, and he helped take the Company public in 2005. Mr. Bonfiglio also led Anthem’s investment in Corus Pharma, and helped engineer the sale of Corus to Gilead.
Prior to joining Anthem, Mr. Bonfiglio was a Partner with Morrison & Foerster, where he worked extensively with technology clients. Mr. Bonfiglio received his B.A. in Mathematics (magna cum laude) from Michigan State University in 1975, and his J.D. (magna cum laude) from the University of Michigan Law School in 1981.